PE20080331A1 - Composiciones farmaceuticas estabilizadas que comprenden fesoterodina - Google Patents

Composiciones farmaceuticas estabilizadas que comprenden fesoterodina

Info

Publication number
PE20080331A1
PE20080331A1 PE2007000695A PE2007000695A PE20080331A1 PE 20080331 A1 PE20080331 A1 PE 20080331A1 PE 2007000695 A PE2007000695 A PE 2007000695A PE 2007000695 A PE2007000695 A PE 2007000695A PE 20080331 A1 PE20080331 A1 PE 20080331A1
Authority
PE
Peru
Prior art keywords
pharmaceutical compositions
compositions including
fesoterodine
stabilized pharmaceutical
composition
Prior art date
Application number
PE2007000695A
Other languages
English (en)
Spanish (es)
Inventor
Christoph Arth
Han-Jurgen Mika
Michael Komenda
Kerstin Paulus
Hans Lindner
Fatima Bicane
Meike Irngartinger
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080331(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of PE20080331A1 publication Critical patent/PE20080331A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2007000695A 2006-06-09 2007-06-06 Composiciones farmaceuticas estabilizadas que comprenden fesoterodina PE20080331A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011941 2006-06-09
EP06011942 2006-06-09
EP06011943 2006-06-09

Publications (1)

Publication Number Publication Date
PE20080331A1 true PE20080331A1 (es) 2008-06-19

Family

ID=38521333

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000695A PE20080331A1 (es) 2006-06-09 2007-06-06 Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
PE2011001996A PE20120476A1 (es) 2006-06-09 2007-06-06 Composiciones farmaceuticas estabilizadas que comprenden fesoterodina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001996A PE20120476A1 (es) 2006-06-09 2007-06-06 Composiciones farmaceuticas estabilizadas que comprenden fesoterodina

Country Status (37)

Country Link
EP (1) EP2029134B1 (enExample)
JP (2) JP4743321B2 (enExample)
KR (1) KR101316773B1 (enExample)
CN (1) CN101466371B (enExample)
AP (1) AP2416A (enExample)
AR (1) AR061289A1 (enExample)
AT (1) ATE517619T1 (enExample)
AU (1) AU2007255408B2 (enExample)
BR (1) BRPI0712865B1 (enExample)
CA (1) CA2652712C (enExample)
CR (1) CR10494A (enExample)
CU (1) CU23850B1 (enExample)
CY (1) CY1111934T1 (enExample)
DK (1) DK2029134T3 (enExample)
EA (1) EA015909B9 (enExample)
EC (1) ECSP089010A (enExample)
ES (1) ES2370943T3 (enExample)
GT (1) GT200800276A (enExample)
HR (1) HRP20110776T1 (enExample)
IL (2) IL195732A (enExample)
MA (1) MA30504B1 (enExample)
MX (1) MX2008015736A (enExample)
MY (1) MY146574A (enExample)
NI (1) NI200800318A (enExample)
NL (1) NL2000690C2 (enExample)
NO (1) NO341980B1 (enExample)
NZ (1) NZ572616A (enExample)
PE (2) PE20080331A1 (enExample)
PL (1) PL2029134T3 (enExample)
PT (1) PT2029134E (enExample)
RS (1) RS51973B (enExample)
SI (1) SI2029134T1 (enExample)
TN (1) TNSN08505A1 (enExample)
TW (2) TWI397409B (enExample)
UY (1) UY30394A1 (enExample)
WO (1) WO2007141298A1 (enExample)
ZA (1) ZA200806411B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009122303A2 (en) * 2008-04-04 2009-10-08 Actavis Group Ptc Ehf Novel mandelate salt of fesoterodine
IT1392082B1 (it) 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
WO2010130392A1 (de) 2009-05-11 2010-11-18 Ratiopharm Gmbh Desfesoterodin in form eines weinsäuresalzes
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20130172411A1 (en) * 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI520732B (zh) * 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
WO2013054337A1 (en) * 2011-07-04 2013-04-18 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
WO2013046194A2 (en) * 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
US20150182629A1 (en) * 2012-07-02 2015-07-02 Hetero Research Foundation Stable compositions of fesoterodine
JP6356684B2 (ja) 2012-11-02 2018-07-11 マレイ・アンド・プール・エンタープライゼズ・リミテッド コルヒチン誘導体の投与による心血管イベントの処置または予防
EA037375B1 (ru) 2013-04-16 2021-03-22 Марри Энд Пул Энтерпрайзес Лимитед Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
ES2870718T3 (es) * 2013-04-16 2021-10-27 Murray & Poole Entpr Ltd Formulación de liberación mantenida de la colchicina y métodos para establecer los mismos
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
CA3094551C (en) 2018-04-26 2024-01-02 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
KR20230028535A (ko) * 2020-06-30 2023-02-28 임브리아 파마슈티칼스, 인크. 트리메타지딘의 변형 형태의 변형 방출 제제
JPWO2023145486A1 (enExample) * 2022-01-28 2023-08-03

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505282A (ja) 1998-03-03 2002-02-19 塩野義製薬株式会社 ホスホリパーゼ阻害剤の［［３−（２−アミノ−１，２−ジオキソエチル）−２−エチル−１−フェニルメチル）−１ｈ−インドール−４−イル］オキシ］酢酸ナトリウムを含む薬学的組成物
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19955190A1 (de) 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Also Published As

Publication number Publication date
IL195732A (en) 2013-09-30
ATE517619T1 (de) 2011-08-15
MA30504B1 (fr) 2009-06-01
NL2000690C2 (nl) 2008-04-01
AU2007255408A1 (en) 2007-12-13
UY30394A1 (es) 2007-11-30
CU20080235A7 (es) 2011-04-26
DK2029134T3 (da) 2011-10-17
EA015909B1 (ru) 2011-12-30
WO2007141298A1 (en) 2007-12-13
CY1111934T1 (el) 2015-11-04
JP4743321B2 (ja) 2011-08-10
RS51973B (sr) 2012-02-29
TNSN08505A1 (fr) 2010-04-14
CA2652712C (en) 2014-04-01
AR061289A1 (es) 2008-08-20
NZ572616A (en) 2010-11-26
EA015909B9 (ru) 2012-03-30
AP2416A (en) 2012-06-01
ECSP089010A (es) 2009-01-30
EA200802444A1 (ru) 2009-06-30
KR20090026135A (ko) 2009-03-11
PL2029134T3 (pl) 2011-12-30
NO341980B1 (no) 2018-03-05
TW201336491A (zh) 2013-09-16
JP2011140498A (ja) 2011-07-21
HK1128626A1 (en) 2009-11-06
CN101466371B (zh) 2011-10-05
TW200814992A (en) 2008-04-01
ES2370943T3 (es) 2011-12-23
EP2029134A1 (en) 2009-03-04
HRP20110776T1 (hr) 2011-11-30
SI2029134T1 (sl) 2012-01-31
AP2008004673A0 (en) 2008-12-31
NO20090141L (no) 2009-01-09
CR10494A (es) 2009-01-19
GT200800276A (es) 2009-06-18
NL2000690A1 (nl) 2007-12-11
ZA200806411B (en) 2009-05-27
EP2029134B1 (en) 2011-07-27
JP4781489B2 (ja) 2011-09-28
IL220800A (en) 2015-03-31
KR101316773B1 (ko) 2013-10-15
TWI520735B (zh) 2016-02-11
JP2009539802A (ja) 2009-11-19
BRPI0712865A2 (pt) 2012-12-18
PT2029134E (pt) 2011-11-02
IL195732A0 (en) 2009-09-01
CA2652712A1 (en) 2007-12-13
PE20120476A1 (es) 2012-04-20
MY146574A (en) 2012-08-30
MX2008015736A (es) 2009-01-09
BRPI0712865B1 (pt) 2021-08-17
CU23850B1 (es) 2012-10-15
AU2007255408B2 (en) 2013-03-14
TWI397409B (zh) 2013-06-01
NI200800318A (es) 2011-01-12
CN101466371A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
PE20080331A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
HN2009000784A (es) Dihidropirazolonas sustituidas
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
DOP2009000135A (es) Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituídos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
SV2008003071A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
PE20090951A1 (es) Suspension pediatrica estabilizada de carisbamato
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
PE20091392A1 (es) Composiciones farmaceuticas como agentes antiinflamatorios
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
EP2515912A4 (en) PHARMACEUTICAL COMPOSITION WITH VITAMIN D ANALOGON AND COLOSTERS-TENSID MIXTURE
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.
AR060869A1 (es) Composicion farmaceutica solida de gabapentina
EP1968566A4 (en) COMPOSITIONS OF CIS-9, TRANS-11 CONJUGATED LINOLIC ACID AND VACCENIC ACID AND ITS USES
EA200701228A1 (ru) Стабильные композиции фенофибрата с эфирами жирных кислот
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
AR070974A1 (es) Formulacion en suspension para adsorbentes de carbono
PA8789401A1 (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FG Grant, registration